Compare Novo Nordisk A/S (NVO) vs First Trust Cloud Computing ETF (SKYY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs First Trust Cloud Computing ETF — how do they compare? Novo Nordisk A/S trades at $38.62 (market cap $165.31B), while First Trust Cloud Computing ETF trades at $175.32 (market cap $3.47B). The key difference: Novo Nordisk A/S is far larger — about 47.6× First Trust Cloud Computing ETF's market cap, and Novo Nordisk A/S pays a 4.71% dividend while First Trust Cloud Computing ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and First Trust Cloud Computing ETF for 85 Days on average.
| NVO | SKYY | |
|---|---|---|
Market Cap | $165.31B | $3.47B |
Volume | 11,432,838 | 176,159 |
Sector | Health | — |
52-Week High | $63.98 | $171.01 |
52-Week Low | $35.29 | $104.16 |
Typical Hold Time | 116 Days | 85 Days |
Enterprise Value | $179.56B | — |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.64, up 0.99% with bearish technical signals despite strong fundamentals. The company maintains exceptional profitability with 35.35% net margins and has beaten earnings estimates for three consecutive quarters. Recent news highlights pipeline developments including weight-loss drug advancements and a $4 billion licensing deal expansion.
While facing competitive pressure in obesity treatments, NVO's valuation remains attractive with a 9.66 P/E ratio. Analyst consensus is bullish with a $44.67 price target, representing 15.6% upside potential. Key risks include FDA regulatory delays and intensifying competition from Eli Lilly in the GLP-1 market.
SKYY (First Trust Cloud Computing ETF) trades at $174.885, up 2.4% with strong bullish technical signals from moving averages. The ETF recently hit a 52-week high, benefiting from AI-driven cloud computing demand. Technical indicators show bullish momentum with support at $169 and resistance at $171. The fund provides diversified exposure to cloud infrastructure and software companies without heavy concentration in mega-cap tech stocks.
The outlook remains positive as cloud computing benefits from secular trends including AI adoption and digital transformation. Key risks include sector concentration and market volatility. Institutional activity shows mixed sentiment with some firms trimming positions while broader analyst coverage highlights the ETF's strategic positioning in the growing cloud computing market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About First Trust Cloud Computing ETF
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index is designed to track the performance of companies involved in the cloud computing industry.
Read more on SKYY →
